Brain Advance Access published online on August 10, 2006
Brain, doi:10.1093/brain/awl207
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Neurosurgery, Sapporo Medical University School of Medicine, Sapporo, Japan
* To whom correspondence should be addressed. Intravenous delivery of mesenchymal stem cells (MSCs) prepared from adult bone marrow reduces infarction size and ameliorates functional deficits in rat cerebral ischaemia models. Placental growth factor (PlGF) is angiogenic to impaired non-neural tissue. To test the hypothesis that PlGF contributes to the therapeutic benefits of MSC delivery in cerebral ischaemia, we compared the efficacy of systemic delivery of human MSCs (hMSCs) and hMSCs transfected with a fibre-mutant F/RGD adenovirus vector with a PlGF gene (PlGF-hMSCs). A permanent middle cerebral artery occlusion (MCAO) was induced by intraluminal vascular occlusion with a microfilament. hMSCs and PlGF-hMSCs were intravenously injected into the rats 3 h after MCAO. Lesion size was assessed at 3 and 6 h, and 1, 3, 4 and 7 days using MR imaging and histology. Functional outcome was assessed using the limb placement test and the treadmill stress test. Both hMSCs and PlGF-hMSCs reduced lesion volume, induced angiogenesis and elicited functional improvement compared with the control sham group, but the effect was greater in the PlGF-hMSC group. Enzyme-linked immunosorbent assay of the infarcted hemisphere revealed an increase in PlGF in both hMSC groups, but a greater increase in the PlGF-hMSC group. These data support the hypothesis that PlGF contributes to neuroprotection and angiogenesis in cerebral ischaemia, and cellular delivery of PlGF to the brain can be achieved by intravenous delivery of hMSCs.
Received January 24, 2006
Accepted June 1, 2006
Article
Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia
H. Liu 1, O. Honmou 2 *, K. Harada 1, K. Nakamura 3, K. Houkin 1, H. Hamada 3, and J. D. Kocsis 4
2 Department of Neurosurgery, Sapporo Medical University School of Medicine, Sapporo, Japan; Department of Neurology, Yale University School of Medicine, New Haven, CT, USA; Neuroscience Research Center, VA Medical Center, West Haven, CT, USA
3 Department of Molecular Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
4 Department of Neurology, Yale University School of Medicine, New Haven, CT, USA; Neuroscience Research Center, VA Medical Center, West Haven, CT, USA
O. Honmou, E-mail: honmou{at}sapmed.ac.jp
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. D. Bull, G. A. Limb, and K. R. Martin Human Muller Stem Cell (MIO-M1) Transplantation in a Rat Model of Glaucoma: Survival, Differentiation, and Integration Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3449 - 3456. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Guzman, A. De Los Angeles, S. Cheshier, R. Choi, S. Hoang, J. Liauw, B. Schaar, and G. Steinberg Intracarotid Injection of Fluorescence Activated Cell-Sorted CD49d-Positive Neural Stem Cells Improves Targeted Cell Delivery and Behavior After Stroke in a Mouse Stroke Model Stroke, April 1, 2008; 39(4): 1300 - 1306. [Abstract] [Full Text] [PDF] |
||||

